Mode
Text Size
Log in / Sign up

Retrospective cohort associates higher NHR with poor functional outcome after acute ischemic stroke reperfusionCould a simple blood ratio predict poor recovery after stroke treatment?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider NHR as a complementary risk marker rather than a standalone predictive or clinical decision-making tool.

This retrospective cohort study evaluated 367 acute ischemic stroke patients with successful reperfusion (mTICI 2b–3) after EVT in a single-center setting. The comparator was baseline clinical predictors. The exposure of interest was the neutrophil-to–high-density lipoprotein cholesterol ratio (NHR). Follow-up duration was 90 days.

The primary outcome was poor functional outcome at 90 days, defined as a modified Rankin Scale score 3–6. Higher NHR was associated with an increased risk of poor functional outcome, with an adjusted odds ratio per 1-unit increase of approximately 1.34. Associations with 90-day mortality and symptomatic intracranial hemorrhage were weaker or attenuated after adjustment.

Key limitations include sparse data at higher NHR levels leading to widened confidence intervals and moderate predictive performance of absolute AUC values. Secondary outcomes included 90-day mortality and symptomatic intracranial hemorrhage (sICH). Discrimination for mortality and sICH was weak to modest. There was a lack of external validation. Safety data regarding adverse events were not reported.

Practice relevance indicates NHR should be interpreted as a complementary risk marker rather than a standalone predictive or clinical decision-making tool. Clinical application requires external validation. The evidence suggests uncertainty due to sparse data at higher NHR levels. Clinicians should recognize the association without inferring causality. Overstating NHR as a standalone predictive or clinical decision-making tool is not supported. Clinical application without external validation is cautioned against.

Imagine a patient who has just survived a stroke and received life-saving treatment to clear their blocked artery. They are hopeful, but can we predict who will struggle to walk or talk normally again? A new look at data from 367 patients at one hospital found that a specific blood measurement, the neutrophil-to-high-density lipoprotein cholesterol ratio, might hold clues. This ratio compares immune cells called neutrophils to the 'good' cholesterol that protects blood vessels.

When patients had higher levels of this ratio, they faced a greater chance of having a poor functional outcome three months later. The study looked at death and bleeding in the brain as well, but the strongest signal was about how well people recovered their daily abilities. However, the data was thin for patients with the highest ratios, making the exact risk numbers less certain.

This does not mean doctors should change how they treat patients right now. The study was done at a single center and needs to be checked in other places first. Think of this blood ratio as a helpful extra piece of information, not a crystal ball. It adds to the picture but cannot replace other clinical judgment or established tools.

What this means for you:
A higher blood ratio linked to worse stroke recovery, but it is not yet a standalone decision tool.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background and objectiveA substantial proportion of patients experience poor functional outcomes despite successful reperfusion after endovascular therapy (EVT) for acute ischemic stroke (AIS). Systemic inflammation and lipid metabolism are thought to contribute to reperfusion-related injury. We aimed to evaluate the association between the neutrophil-to–high-density lipoprotein cholesterol ratio (NHR) and clinical outcomes in AIS patients who achieved successful reperfusion, and to assess its incremental prognostic value beyond established clinical predictors.MethodsIn this single-center retrospective cohort study, 367 AIS patients with successful reperfusion (mTICI 2b–3) after EVT were included. NHR was calculated from baseline blood samples. The primary outcome was poor functional outcome at 90 days (modified Rankin Scale score 3–6). Secondary outcomes included 90-day mortality and symptomatic intracranial hemorrhage (sICH). Associations between NHR and outcomes were examined using logistic regression models with NHR analyzed primarily as a continuous variable, and restricted cubic splines were used to explore potential nonlinearity. Model performance was evaluated by comparing a baseline clinical model with and without NHR using area under the receiver operating characteristic curve (AUC), DeLong tests, calibration metrics, and bootstrap internal validation.ResultsHigher NHR was associated with an increased risk of poor functional outcome after multivariable adjustment (adjusted OR per 1-unit increase, approximately 1.34), indicating a modest effect size. The association with mortality was weaker and showed limited incremental discriminative value beyond baseline clinical predictors. For sICH, the association was attenuated after adjustment and should be interpreted cautiously. Spline analyses suggested possible nonlinearity at higher NHR levels, although confidence intervals widened in these ranges, indicating uncertainty due to sparse data. Adding NHR to the baseline clinical model improved discrimination for poor functional outcome, but the absolute AUC values indicated only moderate predictive performance, and discrimination for mortality and sICH remained weak to modest.ConclusionIn AIS patients who achieved successful reperfusion after EVT, higher NHR was associated with poorer 90-day functional outcomes, with modest effect sizes and limited incremental prognostic value beyond established clinical markers. NHR should be interpreted as a complementary risk marker rather than a standalone predictive or clinical decision-making tool, and external validation is required before any clinical application.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.